Gastroenterology

Medicine & Life Sciences

1. Constipation 100%
2. Fecal Incontinence 79%
3. Manometry 63%
4. Irritable Bowel Syndrome 55%
5. Defecation 47%
6. Rectal Diseases 37%
7. Biofeedback (Psychology) 35%
8. T-Lymphocytes 34%
9. Therapeutics 31%
10. Neoplasms 30%
11. linaclotide 28%
12. Endoscopy 28%
13. Gastroparesis 23%
14. Randomized Controlled Trials 23%
15. Breath Tests 21%
16. Endoscopic Retrograde Cholangiopancreatography 21%
17. Capsules 19%
18. Barrett Esophagus 19%
19. Immunotherapy 18%
20. Abdominal Pain 18%
21. Rifaximin 17%
22. Hemorrhage 17%
23. Defecography 16%
24. Quality of Life 16%
25. Diarrhea 16%
26. Gastroesophageal Reflux 15%
27. Pressure 15%
28. Immunization 15%
29. Colon 14%
30. Ischemic Colitis 14%
31. Deglutition Disorders 14%
32. African Americans 14%
33. Lubiprostone 14%
34. Pelvic Floor 14%
35. Methane 13%
36. Regulatory T-Lymphocytes 13%
37. Gastric Emptying 12%
38. Gastroenterologists 12%
39. Colorectal Neoplasms 12%
40. Laxatives 12%
41. Gases 12%
42. Gastrointestinal Diseases 12%
43. Safety 11%
44. Hepatocellular Carcinoma 11%
45. Digital Rectal Examination 11%
46. Gastrointestinal Motility 11%
47. Stomach 11%
48. Liver 11%
49. Colonic Neoplasms 11%
50. Placebos 11%
51. Proton Pump Inhibitors 11%
52. Alcoholic Hepatitis 11%
53. Lactose Intolerance 11%
54. Immunity 10%
55. Anal Canal 10%
56. Wounds and Injuries 10%
57. Gastroenterology 10%
58. plecanatide 10%
59. Cancer Vaccines 10%
60. Videotape Recording 10%
61. Lactase 9%
62. T-Cell Antigen Receptor 9%
63. Small Intestine 9%
64. Cyclic GMP 9%
65. Pancreatic Neoplasms 9%
66. Pain 9%
67. Practice Guidelines 9%
68. Tumor Necrosis Factor Inhibitors 9%
69. Adenocarcinoma 8%
70. Vaccines 8%
71. Gastrointestinal Microbiome 8%
72. Guidelines 8%
73. Epithelium 8%
74. Costs and Cost Analysis 8%
75. alpha-Fetoproteins 8%
76. Routine Diagnostic Tests 8%
77. Esophageal pH Monitoring 8%
78. Gastrointestinal Tract 8%
79. Dendritic Cells 8%
80. Fructose Intolerance 8%
81. Brain 8%
82. Growth 8%
83. National Institute of Diabetes and Digestive and Kidney Diseases (U.S.) 8%
84. Blood Vessels 8%
85. Population 8%
86. Pancreatitis 8%
87. Pelvic Floor Disorders 8%
88. Diaries 8%
89. Esophagogastric Junction 8%
90. Neoplasm Metastasis 8%
91. Anti-Bacterial Agents 8%
92. Dyspepsia 7%
93. Sildenafil Citrate 7%
94. Muscarinic M1 Receptors 7%
95. Lipoma 7%
96. Prospective Studies 7%
97. Chest Pain 7%
98. Equipment and Supplies 7%
99. Inflammatory Bowel Diseases 7%
100. United States Food and Drug Administration 7%